Jin Woo Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jin Woo Choi has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Hyo-Cheol Kim
Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
20 shared publications Hyo-Cheol Kim
Department of Radiology, Seoul National University Hospital, Seoul, Korea
15 shared publications- Jin Wook Chung
Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
14 shared publications Minseok Suh
Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea
7 shared publicationsHwan Jun Jae
Department of Radiology, Seoul National University Hospital, Seoul, Korea
5 shared publicationsJin Wook Chung
From the Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
5 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in European Radiology
- p. 1-11
Transient flow modulation with rapid-resorbable gelatin microspheres during Yttrium-90 radioembolization for liver cancer: a preliminary clinical trial
Objectives: To explore the effectiveness of rapid-resorbable gelatin microspheres (RGMs) for protecting non-tumorous liver (NTL) through flow modulation during yttrium-90 (Y-90) radioembolization for liver cancer. Materials and methods: This phase II trial defined the primary outcome as the protection rate of RGM-embolized vs non-embolized NTL on Y-90 PET/CT. RGMs (560–800 µm) were used to transiently diminish blood flow to the NTL, followed by Y-90 microsphere administration. The effectiveness of flow modulation and radioembolization was assessed using Y-90 PET/CT and gadoxetic acid-enhanced MRI (EOB-MRI). Results: Twenty patients were enrolled between March 2023 and January 2025. The median protection rate was 35.8% (interquartile range [IQR], 20.2–66.7). Seven patients (35%, 7/20) demonstrated a ≥ 2-fold increase in the tumor-to-NTL uptake ratio on Y-90 PET/CT compared with pre-treatment SPECT/CT. The signal intensity (SI) ratio between protected and unprotected NTLs on the hepatobiliary phase of EOB-MRI increased significantly from baseline (median, 1.03; IQR, 0.97–1.05) to 6-month follow-up (median, 1.29; IQR, 1.18–1.54; p < 0.001). The Y-90 microsphere load to the NTL was negatively correlated with the protection rate ( ρ = −0.578, p = 0.010), whereas the protection rate was positively correlated with the SI ratio at 6 months ( ρ = 0.710, p = 0.001). All patients who underwent subsequent intra-arterial treatments achieved complete arterial recanalization. Conclusion: RGM-mediated flow modulation was associated with reduced Y-90 microsphere deposition in the NTL, with imaging findings suggesting regional liver function preservation. This protective effect appeared greater with lower Y-90 microsphere load. Key Points: Question Can flow modulation using RGMS preserve regional liver function ? Findings Prior embolization with rapidly resorbable gelatin microspheres reduced the absorbed dose to the NTL by 35.8% and preserved signal intensity on EOB-MRI after radioembolization . Clinical relevance RGMs can transiently divert arterial flow away from the NTL, reducing Yttrium-90 microsphere influx and helping preserve regional liver function during Yttrium-90 radioembolization for liver cancer .
- 8 October 2026
- Published by Springer Nature in European Radiology
- p. 1-11
Open AccessTransient flow modulation with rapid-resorbable gelatin microspheres during Yttrium-90 radioembolization for liver cancer: a preliminary clinical trial
Objectives: To explore the effectiveness of rapid-resorbable gelatin microspheres (RGMs) for protecting non-tumorous liver (NTL) through flow modulation during yttrium-90 (Y-90) radioembolization for liver cancer. Materials and methods: This phase II trial defined the primary outcome as the protection rate of RGM-embolized vs non-embolized NTL on Y-90 PET/CT. RGMs (560–800 µm) were used to transiently diminish blood flow to the NTL, followed by Y-90 microsphere administration. The effectiveness of flow modulation and radioembolization was assessed using Y-90 PET/CT and gadoxetic acid-enhanced MRI (EOB-MRI). Results: Twenty patients were enrolled between March 2023 and January 2025. The median protection rate was 35.8% (interquartile range [IQR], 20.2–66.7). Seven patients (35%, 7/20) demonstrated a ≥ 2-fold increase in the tumor-to-NTL uptake ratio on Y-90 PET/CT compared with pre-treatment SPECT/CT. The signal intensity (SI) ratio between protected and unprotected NTLs on the hepatobiliary phase of EOB-MRI increased significantly from baseline (median, 1.03; IQR, 0.97–1.05) to 6-month follow-up (median, 1.29; IQR, 1.18–1.54; p < 0.001). The Y-90 microsphere load to the NTL was negatively correlated with the protection rate ( ρ = −0.578, p = 0.010), whereas the protection rate was positively correlated with the SI ratio at 6 months ( ρ = 0.710, p = 0.001). All patients who underwent subsequent intra-arterial treatments achieved complete arterial recanalization. Conclusion: RGM-mediated flow modulation was associated with reduced Y-90 microsphere deposition in the NTL, with imaging findings suggesting regional liver function preservation. This protective effect appeared greater with lower Y-90 microsphere load. Key Points: Question Can flow modulation using RGMS preserve regional liver function ? Findings Prior embolization with rapidly resorbable gelatin microspheres reduced the absorbed dose to the NTL by 35.8% and preserved signal intensity on EOB-MRI after radioembolization . Clinical relevance RGMs can transiently divert arterial flow away from the NTL, reducing Yttrium-90 microsphere influx and helping preserve regional liver function during Yttrium-90 radioembolization for liver cancer .
- 8 April 2026
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 43 (01) , 005-009
Transarterial Embolization for Chronic Musculoskeletal Pain in the Lower Extremity: Greater Trochanteric Pain Syndrome, Achilles Tendinitis, and Plantar Fasciitis
Transarterial embolization (TAE) has been investigated for chronic lower-extremity musculoskeletal pain refractory to conservative therapy. For greater trochanteric pain syndrome, lateral femoral circumflex artery embolization reduced median visual analog scale scores from 8.5 to 10 to 0 to 2, with clinical success rates of approximately 64% at 30 months. In chronic Achilles tendinopathy and plantar fasciitis, reported success rates range from 73 to 100%, with rapid pain reduction and sustained functional improvement up to 24 to 48 months. Across studies, no major complications were reported. These findings support TAE as a promising option for selected patients, warranting further prospective evaluation.
- 8 April 2026
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 43 (01) , 005-009
Transarterial Embolization for Chronic Musculoskeletal Pain in the Lower Extremity: Greater Trochanteric Pain Syndrome, Achilles Tendinitis, and Plantar Fasciitis
Transarterial embolization (TAE) has been investigated for chronic lower-extremity musculoskeletal pain refractory to conservative therapy. For greater trochanteric pain syndrome, lateral femoral circumflex artery embolization reduced median visual analog scale scores from 8.5 to 10 to 0 to 2, with clinical success rates of approximately 64% at 30 months. In chronic Achilles tendinopathy and plantar fasciitis, reported success rates range from 73 to 100%, with rapid pain reduction and sustained functional improvement up to 24 to 48 months. Across studies, no major complications were reported. These findings support TAE as a promising option for selected patients, warranting further prospective evaluation.
- Open Access
- 1 January 2026
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 111 (1) , 24-32
Laparoscopic versus open liver resection following transarterial radioembolization for hepatocellular carcinoma: a retrospective propensity score-matched study
Sng YP, et al. Ann Surg Treat Res. 2026 Jul;111(1):24-32. https://doi.org/10.4174/astr.2026.111.1.24
- 1 January 2026
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 111 (1) , 24-32
Open AccessLaparoscopic versus open liver resection following transarterial radioembolization for hepatocellular carcinoma: a retrospective propensity score-matched study
Sng YP, et al. Ann Surg Treat Res. 2026 Jul;111(1):24-32. https://doi.org/10.4174/astr.2026.111.1.24
- 19 December 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (3) , 107968
Stepping Up Interventional Radiology Evidence in Budd-Chiari Syndrome
- 19 December 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (3) , 107968
Stepping Up Interventional Radiology Evidence in Budd-Chiari Syndrome
- Open Access
- 17 December 2025
- Published by Springer Nature in EJNMMI Physics
- Vol. 13 (1)
Voxel-based dosimetry for predicting treatment response to transarterial radioembolization in hepatocellular carcinoma: significance of intratumoral dose distribution
We applied a voxel-based personalized dosimetry method using multiple voxel S-values (VSVs) to assess the intratumoral dose distribution in hepatocellular
- 17 December 2025
- Published by Springer Nature in EJNMMI Physics
- Vol. 13 (1)
Open AccessVoxel-based dosimetry for predicting treatment response to transarterial radioembolization in hepatocellular carcinoma: significance of intratumoral dose distribution
We applied a voxel-based personalized dosimetry method using multiple voxel S-values (VSVs) to assess the intratumoral dose distribution in hepatocellular
- 27 August 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (12) , 2010-2020.e2
Same-Day versus Multiday Planning/Treatment Radioembolization with Yttrium-90 Resin Microspheres in Patients with Liver Cancer ≥5 cm
- 27 August 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (12) , 2010-2020.e2
Same-Day versus Multiday Planning/Treatment Radioembolization with Yttrium-90 Resin Microspheres in Patients with Liver Cancer ≥5 cm
- 13 February 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 48 (3) , 398-404
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma with Localized Portal Vein Tumor Thrombosis (RESOLVE): Protocol for an Open-label, Multi-center, Single-arm Trial
To evaluate the efficacy, safety, and clinical course following ablative radioembolization with glass microspheres for hepatocellular carcinoma (HCC) with localized portal vein tumor thrombosis (PVTT) in patients with well-preserved liver function. This is a prospective, open-label, multi-center, single-arm, phase II trial. Key inclusion criteria are unilobar HCC, PVTT confined to the ipsilateral lobe (Vp1-3), no extrahepatic spread, Child-Pugh class A, and a performance status of ≤ 1. Main exclusion criteria are hepatic venous tumor thrombus, bile duct invasion, and massive arterioportal shunting. Depending on the extent of the tumor and PVTT, patients will undergo radiation segmentectomy, modified radiation lobectomy, or ablative lobar treatment, while adhering to dose limits for the non-tumorous liver and lung. The primary outcome measure is overall survival, with the overall survival rate at two years provided as the summary measurement. This study will enroll 30 patients to explore the efficacy and safety of ablative radioembolization for HCC with localized PVTT. Efficacy will be evaluated by intention-to-treat and per-protocol populations. Safety will be assessed for all patients who received radioembolization at any dose. This study aims to address the potential of ablative radioembolization as a definitive or effective downstaging treatment for HCC with localized PVTT, where locoregional treatments may be more beneficial than systemic treatments. The results will help establish treatment outcomes that can serve as a standard for future comparative studies and contribute to the standardization of radioembolization approaches for HCC with localized PVTT. ClinicalTrials.gov ( https://classic. gov/ct2/show/NCT06166576 ). Identifier: NCT06166576.
- 13 February 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 48 (3) , 398-404
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma with Localized Portal Vein Tumor Thrombosis (RESOLVE): Protocol for an Open-label, Multi-center, Single-arm Trial
To evaluate the efficacy, safety, and clinical course following ablative radioembolization with glass microspheres for hepatocellular carcinoma (HCC) with localized portal vein tumor thrombosis (PVTT) in patients with well-preserved liver function. This is a prospective, open-label, multi-center, single-arm, phase II trial. Key inclusion criteria are unilobar HCC, PVTT confined to the ipsilateral lobe (Vp1-3), no extrahepatic spread, Child-Pugh class A, and a performance status of ≤ 1. Main exclusion criteria are hepatic venous tumor thrombus, bile duct invasion, and massive arterioportal shunting. Depending on the extent of the tumor and PVTT, patients will undergo radiation segmentectomy, modified radiation lobectomy, or ablative lobar treatment, while adhering to dose limits for the non-tumorous liver and lung. The primary outcome measure is overall survival, with the overall survival rate at two years provided as the summary measurement. This study will enroll 30 patients to explore the efficacy and safety of ablative radioembolization for HCC with localized PVTT. Efficacy will be evaluated by intention-to-treat and per-protocol populations. Safety will be assessed for all patients who received radioembolization at any dose. This study aims to address the potential of ablative radioembolization as a definitive or effective downstaging treatment for HCC with localized PVTT, where locoregional treatments may be more beneficial than systemic treatments. The results will help establish treatment outcomes that can serve as a standard for future comparative studies and contribute to the standardization of radioembolization approaches for HCC with localized PVTT. ClinicalTrials.gov ( https://classic. gov/ct2/show/NCT06166576 ). Identifier: NCT06166576.
- Open Access
- 1 January 2025
- Published by XMLink in Korean Journal of Radiology
- Vol. 26 (11) , 1043-1053
Post-Treatment PET/CT Dosimetry to Predict Contralateral Lobe Hypertrophy After Transarterial Radioembolization for Hepatocellular Carcinoma
Kang YK, et al. Korean J Radiol. 2025 Sep;26:e77. https://doi.org/10.3348/kjr.2025.0867
- 1 January 2025
- Published by XMLink in Korean Journal of Radiology
- Vol. 26 (11) , 1043-1053
Open AccessPost-Treatment PET/CT Dosimetry to Predict Contralateral Lobe Hypertrophy After Transarterial Radioembolization for Hepatocellular Carcinoma
Kang YK, et al. Korean J Radiol. 2025 Sep;26:e77. https://doi.org/10.3348/kjr.2025.0867